EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study

David Thein iD, Mia-Louise Nielsen iD, Julia-Tatjana Maul iD, Simon Francis Thomsen iD, Jacob P Thyssen iD, Alexander Egeberg iD

Journal of the European Academy of Dermatology and Venereology · 2025-07 · 39 (7) · 1315-1323

DOI: 10.1111/jdv.20259 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 25.07.2024. Verfasst von David Thein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Psoriasis, Biological Products, Dermatologic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is unknown whether the pre‐biologic treatment journey affects subsequent biologic drug survival.

Objective

To examine the potential impact of a complex treatment journey on subsequent biologic drug survival in patients with psoriasis.

Methods

The study utilized longitudinal data from Danish national registries and included all patients who, for the first time, initiated a biological treatment for psoriasis. Maximum follow‐up was 5 years and patients were included from 1 January 2010 to 30 June 2021. The study used three definitions of exposure to a complex treatment journey and the following conventional systemic treatments: acitretin, cyclosporine, dimethyl fumarate and methotrexate. The first definition was the cumulative number of treatment series. The second definition comprised the number of unique treatments. The third definition was time from the first conventional systemic treatment to biological therapy. Drug survival for the three definitions were illustrated using Kaplan–Meier curves and compared using log‐rank test. The sensitivity analysis largely confirmed these findings by grouping patients according to pharmacotherapy.

Results

A total of 2496 patients were included in the study, with 1380 (55.3%) receiving adalimumab, 608 (24.4%) receiving ustekinumab, 271 (10.9%) receiving secukinumab, 166 (6.7%) receiving etanercept and 71 (2.8%) receiving infliximab. The mean age at initiation of biologics was 43.6 years (standard deviation (SD) 15.2 years), and most patients were male (62.9%). During the follow‐up of 5477 patient years, 1953 patients (78.2%) reached the main endpoint of discontinuation. Using a log‐rank test, the probability of remaining on treatment was unaffected by the three definitions of complexity of the treatment journey.

Conclusion

None of the three exposures used to assess the complexity of the pre‐biologic treatment journey appeared to impact drug survival. As long as patients experience adequate disease control, these results suggest that conventional systemic treatment do not negatively impact the drug survival of subsequent biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsDermatologic AgentsHumansMaleFemaleMiddle AgedAdultUstekinumabRegistriesDenmarkEtanerceptCohort StudiesAdalimumabAcitretinAntibodies, Monoclonal, HumanizedMethotrexateAged

Substanzen

Biological ProductsUstekinumabDermatologic AgentsEtanerceptAdalimumabsecukinumabAcitretinAntibodies, Monoclonal, HumanizedMethotrexate

Autor:innen und Institutionen

  • Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology, University of Zürich, Zürich, Switzerland.
  • Faculty of Medicine, University of Zurich, Zürich, Switzerland.
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: David Thein, Mia-Louise Nielsen, Julia-Tatjana Maul, Simon Francis Thomsen, Jacob P Thyssen, Alexander Egeberg

Zitieren

APA

Thein, D., Nielsen, M. L., Maul, J. T., Thomsen, S. F., Thyssen, J. P., & Egeberg, A. (2025). Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study. Journal of the European Academy of Dermatology and Venereology, 39(7), 1315-1323. https://doi.org/10.1111/jdv.20259

Vancouver

Thein D, Nielsen ML, Maul JT, Thomsen SF, Thyssen JP, Egeberg A. Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study. Journal of the European Academy of Dermatology and Venereology. 2025;39(7):1315-1323. doi:10.1111/jdv.20259

BibTeX
@article{Thein2025,
  author = {Thein, David and Nielsen, Mia-Louise and Maul, Julia-Tatjana and Thomsen, Simon Francis and Thyssen, Jacob P and Egeberg, Alexander},
  title = {Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {7},
  pages = {1315--1323},
  doi = {10.1111/jdv.20259}
}
Kostenlos starten →